[Interspecies differences of noopept pharmacokinetics].
Significant interspecific differences in the pharmacokinetics of noopept are manifested by a decrease in the drug elimination rate on the passage from rats to rabbits and humans. Very intensive metabolism of noopept was observed upon intravenous administration in rats. In these animals, presystemic elimination mechanisms lead to the formation of a specific metabolite representing a product of drug biotransformation hydroxylated at the phenyl ring. In rabbits, unchanged noopept circulates in the blood for a longer time upon both intravenous and peroral introduction, biotransformation proceeds at a much slower rate, and no metabolites analogous to that found in rats are detected. The noopept pharmacokinetics in humans differs from that in animals by still slower elimination and considerable individual variability. No drug metabolites are found in the human blood plasma, probably because of a relatively small dose and low concentration.
Boĭko
S S
SS
Laboratory of Pharmacokinetics, Institute of Pharmacology, Russian Academy of Medical Sciences, Baltiiskaya ul. 8, Moscow, 125315 Russia.
Korotkov
S A
SA
Zherdev
V P
VP
Gudasheva
T A
TA
Ostrovskaia
R U
RU
Voronina
T A
TA
D000284:Administration, Oral; D000328:Adult; D000818:Animals; D004151:Dipeptides / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D018697:Nootropic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011817:Rabbits; D051381:Rats; D013045:Species Specificity
D004151:Dipeptides; D018697:Nootropic Agents; C103871:ethyl phenylacetyl-Pro-Gly